Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate whether a systematic IVUS-guided strategy, with prespecified optimization criteria, reduces clinical events compared with conventional angiography in patients undergoing complex PCI.

Cobertura Científica SOLACI ACC 2026

This was a randomized, multicenter clinical trial with 1:1 allocation that included 2,020 patients with silent ischemia, stable or unstable angina, or non–ST-elevation acute coronary syndrome, all with complex coronary lesions. Complexity features included severe calcification, ostial lesions, true bifurcations with branches >2.5 mm, left main coronary artery disease, chronic total occlusions, in-stent restenosis, and long lesions (>28 mm). Patients were assigned to IVUS-guided PCI (n=1,010) or angiography-guided PCI (n=1,010). The mean age was 69 years, 80% were men, with a high prevalence of cardiovascular risk factors and a preserved ejection fraction of approximately 52–53%.

The primary endpoint was target vessel failure, defined as a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target vessel revascularization.

The IVUS-guided strategy demonstrated a significant reduction in the primary endpoint compared with angiography-guided PCI alone. Target vessel failure was lower in the IVUS group (≈7–8%) versus the angiography group (≈10–11%), with a relative reduction of approximately 25–30%.

Read also: ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio.

This difference was mainly driven by a decrease in ischemic events related to the target vessel, particularly a lower need for repeat revascularization and a reduced incidence of target vessel–related myocardial infarction, without a significant increase in periprocedural complications.

Conclusion: Systematic IVUS optimization improves outcomes in complex coronary disease without increasing complications

In conclusion, the IVUS-CHIP trial shows that, in patients with complex coronary artery disease undergoing PCI, a systematic IVUS-guided strategy is associated with a significant reduction in major clinical events compared with conventional angiography.

Original Title: Intravascular Ultrasound Guided or Angiography Guided Complex High-Risk PCI (IVUS-CHIP Trial).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...